(R)-7-chloro-2,2-bis(fluoromethyl)chroman-4-aminium (2S,3S)-3-carboxy-2,3-dihydroxypropanoate | 1221443-98-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (R)-7-chloro-2,2-bis(fluoromethyl)chroman-4-aminium (2S,3S)-3-carboxy-2,3-dihydroxypropanoate
• 英文别名: (4R)-7-chloro-2,2-bis(fluoromethyl)chroman-4-amine D-(-)-tartaric acid；[(4R)-7-chloro-2,2-bis(fluoromethyl)-3,4-dihydrochromen-4-yl]azanium;(2S,3S)-2,3,4-trihydroxy-4-oxobutanoate
• CAS: 1221443-98-6
• 化学式: C₄H₆O₆*C₁₁H₁₂ClF₂NO
• 分子量: 397.76
• InChiKey: YNASYMHMAUJFNR-VXLLBCKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.68
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  155
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  phenyl N-(3-methylisoquinolin-5-yl)carbamate 、 (R)-7-chloro-2,2-bis(fluoromethyl)chroman-4-aminium (2S,3S)-3-carboxy-2,3-dihydroxypropanoate 在 N,N-二异丙基乙胺 作用下， 生成 (R)-1-(7-chloro-2,2-bis(fluoromethyl)-chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea
  参考文献：
  名称：

  Discovery of (R)-1-(7-Chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): A Temperature-Neutral Transient Receptor Potential Vanilloid-1 (TRPV1) Antagonist with Analgesic Efficacy

  摘要：

  The synthesis and characterization of a series of selective, orally bioavailable 1-(chroman-4-yl)urea TRPV1 antagonists is described. Whereas first-generation antagonists that inhibit all modes of TRPV1 activation can elicit hyperthermia, the compounds disclosed herein do not elevate core body temperature in preclinical models and only partially block acid activation of TRPV1. Advancing the SAR of this series led to the eventual identification of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442, 52), an analogue that possesses excellent pharmacological selectivity, has a favorable pharmacokinetic profile, and demonstrates good efficacy against osteoarthritis pain in rodents.

  DOI：

  10.1021/jm500916t

文献信息

• [EN] TRPV1 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV1
  申请人：ABBVIE INC

  公开号：WO2013096226A1

  公开（公告）日：2013-06-27

  Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed. The compounds of formula (I) are useful as TRPV1 antagonists.

  披露了公式(I)的化合物：或其药用可接受的盐，其中X1、L、Rx、Ry、G、Z、A、m、n和p如说明书所述。还披露了包含这些化合物的组合物，以及使用这些化合物和组合物治疗状况和失调的方法。公式(I)的化合物作为TRPV1拮抗剂是有用的。
• TRPV1 ANTAGONISTS
  申请人：AbbVie Inc.

  公开号：US20130172334A1

  公开（公告）日：2013-07-04

  Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X 1 , L, R x , R y , G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文公开了公式(I)的化合物：或其药学上可接受的盐，其中X1，L，Rx，Ry，G，Z，A，m，n和p如规范中定义。还公开了包含这些化合物的组合物以及使用这些化合物和组合物治疗疾病和疾病的方法。
• TRPV1 antagonists
  申请人：AbbVie Inc.

  公开号：US08969325B2

  公开（公告）日：2015-03-03

  Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

  本文揭示了以下式子(I)的化合物：或其药学上可接受的盐，其中X1，L，Rx，Ry，G，Z，A，m，n和p如规范所定义。还揭示了包含这些化合物的组合物以及使用这些化合物和组合物治疗疾病和疾病的方法。